UnicoCell Biomed Co., Ltd. AI Stock Analysis
UnicoCell Biomed Co., Ltd. (6794) AI Stock Analysis
UnicoCell Biomed Co., Ltd.
(TWSE:6794)
UnicoCell Biomed scores low primarily because of weak financial performance: 2025 saw revenue decline, gross profit turn negative, the net loss widen to NT$114.8 million and cash burn accelerate to NT$96.8 million of negative free cash flow, leaving the company reliant on external financing. The main mitigant is a conservative balance sheet with NT$865 million of equity and almost no debt, which funds a multi-year runway. Technicals reinforce caution, with the price below all major moving averages and a negative MACD, though oversold RSI and Stochastic readings hint at a possible near-term bounce. Valuation adds no support given negative earnings and no dividend. Earnings call and corporate events were excluded for lack of data, with their weight redistributed across the remaining components.
UnicoCell Biomed Co., Ltd. (6794) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 4.12B
- Dividend Yield
- ―
- Average Volume (3M)
- 42.02K
- Price to Earnings (P/E)
- -34.1
- Beta (1Y)
- 0.24
- Revenue Growth
- -48.98%
- EPS Growth
- -2.09%
- Country
- TW
- Employees
- 27
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
UnicoCell Biomed Co., Ltd. Business Overview & Revenue Model
Company Description
UnicoCell Biomed Co., Ltd., a Taiwanese enterprise, specializes in the research, development, and application of stem cell-based pharmaceuticals, advanced cell therapy techniques, and regenerative medical solutions. Their flagship product, ELIXCYTE,...
UnicoCell Biomed Co., Ltd. Financial Statement Overview
Summary
A development-stage profile with deteriorating fundamentals. Revenue slipped to NT$30.1 million in 2025 after years of growth, gross profit swung from NT$20.6 million (65% margin) to a small loss, and the net loss widened to NT$114.8 million — roughly four times revenue. Operating cash burn accelerated to NT$91.3 million with free cash flow of negative NT$96.8 million, leaving the business fully dependent on external funding. The clear offset is the balance sheet: NT$865.4 million of equity, NT$946.0 million of assets and minimal debt (debt-to-equity 0.07), providing several years of runway, though equity growth appears driven by share issuance and return on equity remains negative at about -13%.
Income Statement
13Very NegativeBalance Sheet
66PositiveCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.10M | 30.10M | 31.88M | 24.59M | 14.40M | 8.18M |
| Gross Profit | -221.00K | -221.00K | 20.57M | 17.90M | 8.20M | 5.83M |
| EBITDA | -109.73M | -109.73M | -64.03M | -56.28M | -65.63M | -59.45M |
| Net Income | -114.84M | -114.84M | -93.07M | -84.11M | -91.16M | -86.37M |
Balance Sheet | ||||||
| Total Assets | 946.01M | 946.01M | 777.89M | 685.93M | 414.31M | 297.71M |
| Cash, Cash Equivalents and Short-Term Investments | 752.02M | 752.02M | 553.52M | 477.28M | 213.89M | 141.02M |
| Total Debt | 62.02M | 62.02M | 68.24M | 74.33M | 66.59M | 21.58M |
| Total Liabilities | 80.58M | 80.58M | 93.28M | 89.49M | 80.46M | 34.71M |
| Stockholders Equity | 865.43M | 865.43M | 684.61M | 596.44M | 333.85M | 263.00M |
Cash Flow | ||||||
| Free Cash Flow | -75.97M | -96.81M | -67.22M | -81.53M | -78.21M | -85.70M |
| Operating Cash Flow | -74.18M | -91.31M | -61.52M | -65.55M | -63.60M | -61.71M |
| Investing Cash Flow | -300.43M | -173.49M | -122.35M | -307.20M | -164.99M | -23.80M |
| Financing Cash Flow | 176.53M | 296.07M | 173.54M | 339.01M | 151.38M | -5.66M |
UnicoCell Biomed Co., Ltd. Peers Comparison
Overall Rating
TW:176064Neutral
TW:317642Neutral- TW:679440Underperform
TW:472635Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1760 | 64Neutral | TWD 4.23B | 24.71 | ― | 4.19% | 1.43% | -5.24% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:3176 | 42Neutral | TWD 4.62B | -16.65 | ― | ― | 1.11% | -94.39% |
| TW:6794 | 40Underperform | TWD 4.10B | -34.13 | ― | ― | -48.98% | -2.09% |
| TW:4726 | 35Underperform | TWD 4.76B | -12.16 | ― | ― | 52.81% | 38.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6794 | UnicoCell Biomed Co., Ltd. | 64.80 | -6.20 | -8.73% | |
| TW:1760 | Panion & BF Biotech Inc. | 47.70 | -16.06 | -25.18% | |
| TW:3176 | Medigen Biotechnology Corporation | 30.10 | 0.20 | 0.67% | |
| TW:4726 | Mycenax Biotech Inc. | 22.40 | -11.25 | -33.43% | |
| TW:6610 | TWi Biotechnology, Inc | 17.50 | -19.34 | -52.50% | |
| TW:7920 | Tripartite Therapeutics, Inc. | 6.85 | -0.23 | -3.25% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026